SynthesisMedicine2017
A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report.Journal of medical case reports · 2024Article
- Article
- BRAF RNA is prognostic and widely expressed in lung adenocarcinoma.Translational lung cancer research · 2023Article
- Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review.Frontiers in oncology · 2023Review
- Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma.Genes · 2022Article
- Thyroid carcinoma associated with other primary neoplasms, a single center study.Medicine and pharmacy reports · 2022Article
- Immune biomarkers and response to checkpoint inhibition of BRAFBritish journal of cancer · 2022Article
- [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Review
- Treatment of Rare Mutations in Patients with Lung Cancer.Biomedicines · 2021Review
- Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other ThanFrontiers in oncology · 2021Review
- A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening.Scientific reports · 2020Article
- Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.Current treatment options in oncology · 2020Review
- Targeting BRAF mutations in non-small cell lung cancer.Translational lung cancer research · 2019Review
- Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.Current problems in cancer · 2019Article
- Article
- Validation of Immunohistochemistry for the Detection ofCancers · 2019Article
- Sexual dimorphism in solid and hematological malignancies.Seminars in immunopathology · 2019Review
- Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer WithJCO precision oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies investigating the association between BRAF mutations and nonsmall cell lung cancer (NSCLC) remain controversial. To address the issue, we performed an updated meta-analysis of related articles.
methodsWe conducted a comprehensive literature search in the electronic databases including ISI Science Citation Index, EMBASE, PubMed, and CNKI (up to January 2016). The odds ratios (ORs) and 95% confidence interval (CI) were assessed based on random-effects or fixed-effects models according to the heterogeneity of eligible studies.
resultsA total of 16 studies enrolled 11,711 patients with NSCLC were involved in the meta-analysis. The overall BRAF mutation rate was 2.6% (303/11,711). There was a significant association between BRAF mutations and adenocarcinomas (ADCs) in NSCLC compared with non-ADCs (OR = 3.96, 95% CI = 2.13-7.34, P < 0.0001). No significant difference was observed in smoking and stage in patients with BRAF mutations. However, a significant difference of BRAF mutation rate was observed between women and men (OR = 0.72, 95% CI = 0.55-0.95, P = 0.02). In addition, the BRAF mutations were more frequent in women (OR = 0.45, 95% CI = 0.26-0.77, P = 0.004) and never smokers (OR = 0.12, 95% CI = 0.05-0.29, P < 0.00001).
conclusionsBRAF mutations in ADCS and female significantly increased the risk of NSCLC compared to non-ADCS and male, respectively. BRAFV mutation in NSCLC patients was significantly associated with female and nonsmokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.